Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Biobanking for Metabolomics and Lipidomics in Precision Medicine.

Kirwan JA, Kaddurah-Daouk R, Mitchell T, Pischon T, Schmidt MA, Velagapudi V.

Clin Chem. 2019 May 14. pii: clinchem.2018.298620. doi: 10.1373/clinchem.2018.298620. [Epub ahead of print] No abstract available.

PMID:
31088785
2.

Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders.

Steen NE, Dieset I, Hope S, Vedal TSJ, Smeland OB, Matson W, Kaddurah-Daouk R, Agartz I, Melle I, Djurovic S, Jönsson EG, Bogdanov M, Andreassen OA.

Psychol Med. 2019 Mar 14:1-12. doi: 10.1017/S0033291719000400. [Epub ahead of print]

PMID:
30867076
3.

Systematic Error Removal Using Random Forest for Normalizing Large-Scale Untargeted Lipidomics Data.

Fan S, Kind T, Cajka T, Hazen SL, Tang WHW, Kaddurah-Daouk R, Irvin MR, Arnett DK, Barupal DK, Fiehn O.

Anal Chem. 2019 Mar 5;91(5):3590-3596. doi: 10.1021/acs.analchem.8b05592. Epub 2019 Feb 19.

PMID:
30758187
4.

Augmentation of Physician Assessments with Multi-Omics Enhances Predictability of Drug Response: A Case Study of Major Depressive Disorder.

Athreya A, Iyer R, Neavin D, Wang L, Weinshilboum R, Kaddurah-Daouk R, Rush J, Frye M, Bobo W.

IEEE Comput Intell Mag. 2018 Aug;13(3):20-31. doi: 10.1109/MCI.2018.2840660. Epub 2018 Jul 20.

PMID:
30467458
5.

Generation and quality control of lipidomics data for the alzheimer's disease neuroimaging initiative cohort.

Barupal DK, Fan S, Wancewicz B, Cajka T, Sa M, Showalter MR, Baillie R, Tenenbaum JD, Louie G; Alzheimer’s Disease Neuroimaging Initiative; Alzheimer’s Disease Metabolomics Consortium, Kaddurah-Daouk R, Fiehn O.

Sci Data. 2018 Nov 20;5:180263. doi: 10.1038/sdata.2018.263.

6.

Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.

Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, Blach C, Baillie R, Han X, Kastenmüller G, Jia W, Xie G, Ahmad S, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, Saykin AJ, Kaddurah-Daouk R; Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.

Alzheimers Dement. 2019 Feb;15(2):232-244. doi: 10.1016/j.jalz.2018.08.012. Epub 2018 Oct 15.

7.

Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome.

MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, Louie G, Kueider-Paisley A, Moseley MA, Thompson JW, St John Williams L, Tenenbaum JD, Blach C, Baillie R, Han X, Bhattacharyya S, Toledo JB, Schafferer S, Klein S, Koal T, Risacher SL, Kling MA, Motsinger-Reif A, Rotroff DM, Jack J, Hankemeier T, Bennett DA, De Jager PL, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, van Duijn CM, Saykin AJ, Kastenmüller G, Kaddurah-Daouk R; Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.

Alzheimers Dement. 2019 Jan;15(1):76-92. doi: 10.1016/j.jalz.2018.07.217. Epub 2018 Oct 15. Erratum in: Alzheimers Dement. 2019 Apr;15(4):604.

8.

Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate.

Kaddurah-Daouk R, Hankemeier T, Scholl EH, Baillie R, Harms A, Stage C, Dalhoff KP, Jűrgens G, Taboureau O, Nzabonimpa GS, Motsinger-Reif AA, Thomsen R, Linnet K, Rasmussen HB; INDICES Consortium; Pharmacometabolomics Research Network.

CPT Pharmacometrics Syst Pharmacol. 2018 Aug;7(8):525-533. doi: 10.1002/psp4.12309.

9.

Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders.

Ahmed AT, Frye MA, Rush AJ, Biernacka JM, Craighead WE, McDonald WM, Bobo WV, Riva-Posse P, Tye SJ, Mayberg HS, Hall-Flavin DK, Skime MK, Jenkins GD, Wang L, Krishnan RR, Weinshilboum RM, Kaddurah-Daouk R, Dunlop BW; Mood Disorders Precision Medicine Consortium (MDPMC).

J Affect Disord. 2018 Oct 1;238:1-7. doi: 10.1016/j.jad.2018.05.005. Epub 2018 May 26.

PMID:
29807322
10.

Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression.

Ho MF, Correia C, Ingle JN, Kaddurah-Daouk R, Wang L, Kaufmann SH, Weinshilboum RM.

Biochem Pharmacol. 2018 Jun;152:279-292. doi: 10.1016/j.bcp.2018.03.032. Epub 2018 Apr 3.

PMID:
29621538
11.

Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study.

Varma VR, Oommen AM, Varma S, Casanova R, An Y, Andrews RM, O'Brien R, Pletnikova O, Troncoso JC, Toledo J, Baillie R, Arnold M, Kastenmueller G, Nho K, Doraiswamy PM, Saykin AJ, Kaddurah-Daouk R, Legido-Quigley C, Thambisetty M.

PLoS Med. 2018 Jan 25;15(1):e1002482. doi: 10.1371/journal.pmed.1002482. eCollection 2018 Jan.

12.

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics.

Liu D, Ray B, Neavin DR, Zhang J, Athreya AP, Biernacka JM, Bobo WV, Hall-Flavin DK, Skime MK, Zhu H, Jenkins GD, Batzler A, Kalari KR, Boakye-Agyeman F, Matson WR, Bhasin SS, Mushiroda T, Nakamura Y, Kubo M, Iyer RK, Wang L, Frye MA, Kaddurah-Daouk R, Weinshilboum RM.

Transl Psychiatry. 2018 Jan 10;8(1):10. doi: 10.1038/s41398-017-0056-8.

13.

Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics.

Shahin MH, Gong Y, Frye RF, Rotroff DM, Beitelshees AL, Baillie RA, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Motsinger-Reif A, Fiehn O, Cooper-DeHoff RM, Han X, Kaddurah-Daouk R, Johnson JA.

J Am Heart Assoc. 2017 Dec 29;7(1). pii: e006656. doi: 10.1161/JAHA.117.006656.

14.

Targeted metabolomics and medication classification data from participants in the ADNI1 cohort.

St John-Williams L, Blach C, Toledo JB, Rotroff DM, Kim S, Klavins K, Baillie R, Han X, Mahmoudiandehkordi S, Jack J, Massaro TJ, Lucas JE, Louie G, Motsinger-Reif AA, Risacher SL; Alzheimer’s Disease Neuroimaging Initiative; Alzheimer’s Disease Metabolomics Consortium, Saykin AJ, Kastenmüller G, Arnold M, Koal T, Moseley MA, Mangravite LM, Peters MA, Tenenbaum JD, Thompson JW, Kaddurah-Daouk R.

Sci Data. 2017 Oct 17;4:170140. doi: 10.1038/sdata.2017.140.

15.

The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia.

Réus GZ, Becker IRT, Scaini G, Petronilho F, Oses JP, Kaddurah-Daouk R, Ceretta LB, Zugno AI, Dal-Pizzol F, Quevedo J, Barichello T.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:55-63. doi: 10.1016/j.pnpbp.2017.10.009. Epub 2017 Oct 13.

PMID:
29030243
16.

The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback.

Nguyen TV, Reuter JM, Gaikwad NW, Rotroff DM, Kucera HR, Motsinger-Reif A, Smith CP, Nieman LK, Rubinow DR, Kaddurah-Daouk R, Schmidt PJ.

Transl Psychiatry. 2017 Aug 8;7(8):e1193. doi: 10.1038/tp.2017.146.

17.

Ketamine potentiates oxidative stress and influences behavior and inflammation in response to lipolysaccharide (LPS) exposure in early life.

Réus GZ, Simões LR, Colpo GD, Scaini G, Oses JP, Generoso JS, Prossin AR, Kaddurah-Daouk R, Quevedo J, Barichello T.

Neuroscience. 2017 Jun 14;353:17-25. doi: 10.1016/j.neuroscience.2017.04.016. Epub 2017 Apr 20.

PMID:
28433652
18.

Metabolic network failures in Alzheimer's disease: A biochemical road map.

Toledo JB, Arnold M, Kastenmüller G, Chang R, Baillie RA, Han X, Thambisetty M, Tenenbaum JD, Suhre K, Thompson JW, John-Williams LS, MahmoudianDehkordi S, Rotroff DM, Jack JR, Motsinger-Reif A, Risacher SL, Blach C, Lucas JE, Massaro T, Louie G, Zhu H, Dallmann G, Klavins K, Koal T, Kim S, Nho K, Shen L, Casanova R, Varma S, Legido-Quigley C, Moseley MA, Zhu K, Henrion MYR, van der Lee SJ, Harms AC, Demirkan A, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Saykin AJ, Weiner MW, Doraiswamy PM, Kaddurah-Daouk R; Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.

Alzheimers Dement. 2017 Sep;13(9):965-984. doi: 10.1016/j.jalz.2017.01.020. Epub 2017 Mar 22.

19.

Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.

de Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM.

Metabolomics. 2016 Aug;12(8). pii: 129. doi: 10.1007/s11306-016-1076-8. Epub 2016 Jul 13.

20.

Pharmacometabolomic signature links simvastatin therapy and insulin resistance.

Elbadawi-Sidhu M, Baillie RA, Zhu H, Chen YI, Goodarzi MO, Rotter JI, Krauss RM, Fiehn O, Kaddurah-Daouk R.

Metabolomics. 2017 Jan;13. pii: 11. Epub 2016 Dec 23.

21.

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.

Rotroff DM, Corum DG, Motsinger-Reif A, Fiehn O, Bottrel N, Drevets WC, Singh J, Salvadore G, Kaddurah-Daouk R.

Transl Psychiatry. 2016 Sep 20;6(9):e894. doi: 10.1038/tp.2016.145.

22.

Metabolomics enables precision medicine: "A White Paper, Community Perspective".

Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, Brennan L, Wishart DS, Oresic M, Hankemeier T, Broadhurst DI, Lane AN, Suhre K, Kastenmüller G, Sumner SJ, Thiele I, Fiehn O, Kaddurah-Daouk R; for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative.

Metabolomics. 2016;12(10):149. Epub 2016 Sep 2.

23.

Pharmacometabolomics informs Pharmacogenomics.

Neavin D, Kaddurah-Daouk R, Weinshilboum R.

Metabolomics. 2016 Jul;12(7). pii: 121. Epub 2016 Jul 1.

24.

A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration.

Shahin MH, Gong Y, McDonough CW, Rotroff DM, Beitelshees AL, Garrett TJ, Gums JG, Motsinger-Reif A, Chapman AB, Turner ST, Boerwinkle E, Frye RF, Fiehn O, Cooper-DeHoff RM, Kaddurah-Daouk R, Johnson JA.

Hypertension. 2016 Sep;68(3):621-9. doi: 10.1161/HYPERTENSIONAHA.116.07328. Epub 2016 Jul 5.

25.

Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans.

Rotroff DM, Oki NO, Liang X, Yee SW, Stocker SL, Corum DG, Meisner M, Fiehn O, Motsinger-Reif AA, Giacomini KM, Kaddurah-Daouk R.

Front Pharmacol. 2016 Jun 14;7:135. doi: 10.3389/fphar.2016.00135. eCollection 2016.

26.

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.

Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV, Frye MA, Skime M, Jenkins GD, Batzler A, Kalari K, Matson W, Bhasin SS, Zhu H, Mushiroda T, Nakamura Y, Kubo M, Wang L, Kaddurah-Daouk R, Weinshilboum RM.

Mol Psychiatry. 2016 Dec;21(12):1717-1725. doi: 10.1038/mp.2016.6. Epub 2016 Feb 23.

27.

Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes.

Rotroff DM, Shahin MH, Gurley SB, Zhu H, Motsinger-Reif A, Meisner M, Beitelshees AL, Fiehn O, Johnson JA, Elbadawi-Sidhu M, Frye RF, Gong Y, Weng L, Cooper-DeHoff RM, Kaddurah-Daouk R.

CPT Pharmacometrics Syst Pharmacol. 2015 Nov;4(11):669-79. doi: 10.1002/psp4.12017. Epub 2015 Oct 29.

28.

Quality assurance of metabolomics.

Bouhifd M, Beger R, Flynn T, Guo L, Harris G, Hogberg H, Kaddurah-Daouk R, Kamp H, Kleensang A, Maertens A, Odwin-DaCosta S, Pamies D, Robertson D, Smirnova L, Sun J, Zhao L, Hartung T.

ALTEX. 2015;32(4):319-26. doi: 10.14573/altex.1509161.

29.

Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians.

Kim S, Nho K, Ramanan VK, Lai D, Foroud TM, Lane K, Murrell JR, Gao S, Hall KS, Unverzagt FW, Baiyewu O, Ogunniyi A, Gureje O, Kling MA, Doraiswamy PM, Kaddurah-Daouk R, Hendrie HC, Saykin AJ.

J Alzheimers Dis. 2016;49(4):991-1003. doi: 10.3233/JAD-150651.

30.

Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study.

Ellero-Simatos S, Beitelshees AL, Lewis JP, Yerges-Armstrong LM, Georgiades A, Dane A, Harms AC, Strassburg K, Guled F, Hendriks MM, Horenstein RB, Shuldiner AR, Hankemeier T, Kaddurah-Daouk R; Pharmacometabolomics Research Network.

J Am Heart Assoc. 2015 Oct 26;4(10):e002203. doi: 10.1161/JAHA.115.002203.

31.

Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.

Saykin AJ, Shen L, Yao X, Kim S, Nho K, Risacher SL, Ramanan VK, Foroud TM, Faber KM, Sarwar N, Munsie LM, Hu X, Soares HD, Potkin SG, Thompson PM, Kauwe JS, Kaddurah-Daouk R, Green RC, Toga AW, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):792-814. doi: 10.1016/j.jalz.2015.05.009. Review.

32.

Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review.

Emwas AH, Luchinat C, Turano P, Tenori L, Roy R, Salek RM, Ryan D, Merzaban JS, Kaddurah-Daouk R, Zeri AC, Nagana Gowda GA, Raftery D, Wang Y, Brennan L, Wishart DS.

Metabolomics. 2015;11(4):872-894. Epub 2014 Nov 21. Review.

33.

Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.

Rasmussen HB, Bjerre D, Linnet K, Jürgens G, Dalhoff K, Stefansson H, Hankemeier T, Kaddurah-Daouk R, Taboureau O, Brunak S, Houmann T, Jeppesen P, Pagsberg AK, Plessen K, Dyrborg J, Hansen PR, Hansen PE, Hughes T, Werge T; INDICES Consortium.

Pharmacogenomics. 2015;16(6):649-65. doi: 10.2217/pgs.15.7. Epub 2015 Apr 21. Review.

PMID:
25896426
34.

Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine.

Kaddurah-Daouk R, Weinshilboum R; Pharmacometabolomics Research Network.

Clin Pharmacol Ther. 2015 Jul;98(1):71-5. doi: 10.1002/cpt.134. Epub 2015 Jun 4. Review.

35.

Module-based association analysis for omics data with network structure.

Wang Z, Maity A, Hsiao CK, Voora D, Kaddurah-Daouk R, Tzeng JY.

PLoS One. 2015 Mar 30;10(3):e0122309. doi: 10.1371/journal.pone.0122309. eCollection 2015.

36.

Introducing the USA Plant, Algae and Microbial Metabolomics Research Coordination Network (PAMM-NET).

Sumner LW, Styczynski M, McLean J, Fiehn O, Jander G, Liao J, Sumner S, Britz-McKibbin P, Welti R, Jones AD, Dorrestein PC, Bearden D, Kaddurah-Daouk R.

Metabolomics. 2015 Feb;11(1):3-5. doi: 10.1007/s11306-014-0755-6. Epub 2014 Dec 20. No abstract available.

37.

Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability.

Ellero-Simatos S, Lewis JP, Georgiades A, Yerges-Armstrong LM, Beitelshees AL, Horenstein RB, Dane A, Harms AC, Ramaker R, Vreeken RJ, Perry CG, Zhu H, Sànchez CL, Kuhn C, Ortel TL, Shuldiner AR, Hankemeier T, Kaddurah-Daouk R.

CPT Pharmacometrics Syst Pharmacol. 2014 Jul 16;3:e125. doi: 10.1038/psp.2014.22.

38.

Associations between central nervous system serotonin, fasting glucose, and hostility in African American females.

Boyle SH, Georgiades A, Brummett BH, Barefoot JC, Siegler IC, Matson WR, Kuhn CM, Grichnik K, Stafford-Smith M, Williams RB, Kaddurah-Daouk R, Surwit RS.

Ann Behav Med. 2015 Feb;49(1):49-57. doi: 10.1007/s12160-014-9626-7.

39.

Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose?

Cooper-Dehoff RM, Hou W, Weng L, Baillie RA, Beitelshees AL, Gong Y, Shahin MH, Turner ST, Chapman A, Gums JG, Boyle SH, Zhu H, Wikoff WR, Boerwinkle E, Fiehn O, Frye RF, Kaddurah-Daouk R, Johnson JA.

Circ Cardiovasc Genet. 2014 Apr;7(2):199-205. doi: 10.1161/CIRCGENETICS.113.000421. Epub 2014 Mar 13.

40.

Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging.

Motsinger-Reif AA, Zhu H, Kling MA, Matson W, Sharma S, Fiehn O, Reif DM, Appleby DH, Doraiswamy PM, Trojanowski JQ, Kaddurah-Daouk R, Arnold SE.

Acta Neuropathol Commun. 2013 Jun 27;1:28. doi: 10.1186/2051-5960-1-28.

41.

Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.

Kaddurah-Daouk R, Weinshilboum RM; Pharmacometabolomics Research Network.

Clin Pharmacol Ther. 2014 Feb;95(2):154-67. doi: 10.1038/clpt.2013.217. Epub 2013 Nov 5. Review.

PMID:
24193171
42.

Pharmacometabolomics of statin response.

Krauss RM, Zhu H, Kaddurah-Daouk R.

Clin Pharmacol Ther. 2013 Nov;94(5):562-5. doi: 10.1038/clpt.2013.164. Epub 2013 Aug 14. Review.

43.

Pharmacometabolomic signature of ataxia SCA1 mouse model and lithium effects.

Perroud B, Jafar-Nejad P, Wikoff WR, Gatchel JR, Wang L, Barupal DK, Crespo-Barreto J, Fiehn O, Zoghbi HY, Kaddurah-Daouk R.

PLoS One. 2013 Aug 2;8(8):e70610. doi: 10.1371/journal.pone.0070610. Print 2013.

44.

Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics.

McEvoy J, Baillie RA, Zhu H, Buckley P, Keshavan MS, Nasrallah HA, Dougherty GG, Yao JK, Kaddurah-Daouk R.

PLoS One. 2013 Jul 24;8(7):e68717. doi: 10.1371/journal.pone.0068717. Print 2013.

45.

Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy.

Lewis JP, Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Kaddurah-Daouk R, Hankemeier T.

Clin Pharmacol Ther. 2013 Nov;94(5):570-3. doi: 10.1038/clpt.2013.153. Epub 2013 Jul 26. Review. No abstract available.

46.

Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway.

Zhu H, Bogdanov MB, Boyle SH, Matson W, Sharma S, Matson S, Churchill E, Fiehn O, Rush JA, Krishnan RR, Pickering E, Delnomdedieu M, Kaddurah-Daouk R; Pharmacometabolomics Research Network.

PLoS One. 2013 Jul 17;8(7):e68283. doi: 10.1371/journal.pone.0068283. Print 2013.

47.

Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics.

Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Zhu H, Lewis JP, Horenstein RB, Beitelshees AL, Dane A, Reijmers T, Hankemeier T, Fiehn O, Shuldiner AR, Kaddurah-Daouk R.

Clin Pharmacol Ther. 2013 Oct;94(4):525-32. doi: 10.1038/clpt.2013.119. Epub 2013 Jun 11.

48.

Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis.

Yao JK, Dougherty GG, Reddy RD, Matson WR, Kaddurah-Daouk R, Keshavan MS.

Front Cell Neurosci. 2013 Jun 11;7:90. doi: 10.3389/fncel.2013.00090. eCollection 2013.

49.

Alterations in metabolic pathways and networks in Alzheimer's disease.

Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, Oki NO, Motsinger-Reif AA, Churchill E, Lei Z, Appleby D, Kling MA, Trojanowski JQ, Doraiswamy PM, Arnold SE; Pharmacometabolomics Research Network.

Transl Psychiatry. 2013 Apr 9;3:e244. doi: 10.1038/tp.2013.18.

50.

Pharmacometabolomics reveals racial differences in response to atenolol treatment.

Wikoff WR, Frye RF, Zhu H, Gong Y, Boyle S, Churchill E, Cooper-Dehoff RM, Beitelshees AL, Chapman AB, Fiehn O, Johnson JA, Kaddurah-Daouk R; Pharmacometabolomics Research Network.

PLoS One. 2013;8(3):e57639. doi: 10.1371/journal.pone.0057639. Epub 2013 Mar 11.

Supplemental Content

Loading ...
Support Center